menu

Loading...

MANE Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

45.880

Open

42.580

VWAP

44.77

Vol

279.38K

Mkt Cap

1.61B

Low

42.580

Amount

12.51M

EV/EBITDA(TTM)

--

Total Shares

35.08M

EV

1.81B

EV/OCF(TTM)

--

P/S(TTM)

--

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

Show More

Events Timeline

(ET)

2026-02-09

11:10:00

SpyGlass Pharma Surges Over 60% on First Trading Day

2026-02-09

07:40:00

Veradermics Completes Enrollment in Second Phase 3 Trial for VDPHL01

2026-02-04 (ET)

2026-02-04

13:30:00

Veradermics Prices 15.08M Shares at $17.00

2026-02-04

12:40:00

Veradermics IPO Priced at $17, Expected Opening at $32-$34

2026-02-04

11:20:00

Veradermics Prices 15.08M Shares at $17.00

2026-02-03 (ET)

2026-02-03

23:20:00

Deal Size Increased to 15.1M Shares

News

Barron's

Anthropic's Valuation Reaches $380 Billion as AI Thrives Amid Software Struggles

Newsfilter

02-09Newsfilter

Completion of VDPHL01 Phase 3 Enrollment for Male Pattern Hair Loss

Barron's

Jennifer Garner's Once Upon a Farm Sees Nearly 20% Increase as IPO Week Concludes

Barron's

Amazon Takes Bold Steps in AI Investment, Posing Significant Risks for Markets.

Barron's

Three Companies Make Their Debut Today as the IPO Market Gains Momentum: SpaceX, OpenAI, and Anthropic on the Horizon.

seekingalpha

02-04seekingalpha

Veradermics Doubles in Value on First Trading Day

0 Analyst Rating

Wall Street analysts forecast MANE stock price to rise

0 Buy

0 Hold

0 Sell

Current: 0.000

Low

Averages

High

Current: 0.000

Low

Averages

High

Jefferies

initiated

$75

AI Analysis

2026-03-02

New

Reason

Jefferies

Price Target

$75

AI Analysis

2026-03-02

New

initiated

Reason

Jefferies initiated coverage of Veradermics with a Buy rating and $75 price target. The firm thinks the company's Phase 3 study has a high likelihood of success. The company's VDPHL01 extended release enables sustained plasma concentrations, the analyst tells investors in a research note.

Citi

NULL

to

Buy

initiated

$85

2026-03-02

New

Reason

Citi

Price Target

$85

2026-03-02

New

initiated

NULL

to

Buy

Reason

Citi initiated coverage of Veradermics with a Buy rating and $85 price target. The firm believes the company's VDPHL01 is positioned to become the first FDA-approved oral minoxidil for pattern hair loss. The drug will enter a $30B market with a major unmet need, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MANE

Unlock Now

Valuation Metrics

The current forward P/E ratio for Veradermics Inc (MANE.N) is --, compared to its 5-year average forward P/E of --. For a more detailed relative valuation and DCF analysis to assess Veradermics Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

5Y Average PE

Current PE

NaN

Overvalued PE

Undervalued PE

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

5Y Average EV/EBITDA

Current EV/EBITDA

NaN

Overvalued EV/EBITDA

Undervalued EV/EBITDA

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

5Y Average PS

Current PS

NaN

Overvalued PS

Undervalued PS

Financials

AI Analysis

Annual

Quarterly

Whales Holding MANE

Suvretta Capital Management, LLC

Trading Trends

People Also Watch

Frequently Asked Questions

What is Veradermics Inc (MANE) stock price today?

The current price of MANE is 45.85 USD — it has increased 6.85

What is Veradermics Inc (MANE)'s business?

Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.

What is the price predicton of MANE Stock?

Wall Street analysts forecast MANE stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MANE is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Veradermics Inc (MANE)'s revenue for the last quarter?

Veradermics Inc revenue for the last quarter amounts to -5.97M USD, decreased

What is Veradermics Inc (MANE)'s earnings per share (EPS) for the last quarter?

Veradermics Inc. EPS for the last quarter amounts to USD, decreased

How many employees does Veradermics Inc (MANE). have?

Veradermics Inc (MANE) has 19 emplpoyees as of March 02 2026.

What is Veradermics Inc (MANE) market cap?

Today MANE has the market capitalization of 1.61B USD.